More than 60% of LUAD can be identified by driving mutations, epidermal growth factor receptor (EGFR), ALK, and other driver gene mutations, which significantly improved survival in patients with LUAD; however, for LUSC, accounting for one‐third of NSCLC, the driver genes such as EGFR mutations and ALK gene rearrangements are rarely detected.3 The gene discussed is ALK; the disease is non-small cell lung carcinoma.